We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ZYN and IQOS Scale Up: Is Philip Morris Leading the Industry Reset?
Read MoreHide Full Article
Key Takeaways
PM's smoke-free products made up 44% of Q1 gross profit, led by IQOS and ZYN shipments.
ZYN shipments soared 53% in Q1, with PM raising 2025 shipment guidance to 800-840 million cans.
PM's smoke-free gross margin topped 70%, far exceeding combustibles, with products in 95 markets.
Philip Morris International Inc. (PM - Free Report) is accelerating its shift from traditional tobacco to reduced-risk products, with strong momentum in its flagship offerings — IQOS and ZYN. In the first quarter of 2025, smoke-free products accounted for 44% of the company’s total gross profit, signaling significant progress toward its goal of becoming substantially smoke-free.
IQOS, Philip Morris’ heat-not-burn device, continues to be a global leader in next-gen nicotine delivery, delivering 9.4% growth in HTU-adjusted IMS, bolstered by solid performances in Japan and Europe. Meanwhile, ZYN, the oral nicotine pouch under Swedish Match (acquired in 2022), is quickly becoming a dominant force in the U.S. nicotine market. ZYN shipments surged 53% year over year to 202 million cans, with Philip Morris now expecting 800-840 million cans shipped in 2025, up from its prior forecast.
This surge is not just about volume — Philip Morris is seeing bottom-line benefits too. Smoke-free organic revenues rose 20.4%, while gross profit jumped 33.1%, pushing gross margin over 70%, far surpassing margins from combustible products. PM’s multi-category strategy — which also includes VEEV in the e-vapor space — is gaining traction, and its smoke-free products are now available in 95 countries with 38.6 million adult users globally.
With robust growth, margin expansion and strategic manufacturing investments in the United States, Philip Morris appears well-positioned to future-proof its portfolio. If current trends hold, the company could redefine its identity in a post-combustible world.
Altria & British American Tobacco Step Up Smoke-Free Competition
As Philip Morris pushes ahead in the smoke-free nicotine market, key rivals Altria Group, Inc. (MO - Free Report) and British American Tobacco p.l.c. (BTI - Free Report) are also accelerating their transition. Altria, known for Marlboro in the United States, is expanding its smoke-free portfolio through Helix Innovations, which owns 100% of on! nicotine pouches. In first-quarter 2025, on! shipments rose 18% year over year, driving stable growth in Altria’s Oral Tobacco segment, which posted $654 million in net revenues.
Meanwhile, British American Tobacco is targeting 50 million users of smoke-free products by 2030 and aims to generate 50% of revenues from this segment by 2035. In 2024, British American Tobacco’s New Category segment grew 2.5%, with 29.1 million adult users across products like Vuse (vapor), glo (heated) and Velo (oral nicotine). With both companies investing heavily in reduced-risk products, competition in the global smoke-free nicotine market continues to intensify.
PM’s Price Performance, Valuation & Estimates
Shares of Philip Morris have rallied 52.3% year to date compared with the industry’s growth of 37%.
Image Source: Zacks Investment Research
From a valuation standpoint, PM trades at a forward price-to-earnings ratio of 23.34X, above the industry’s average of 15.33X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for PM’s 2025 earnings implies year-over-year growth of 13.7%, whereas its 2026 earnings estimate suggests a year-over-year uptick of 11.7%. The estimates for 2025 and 2026 have remained unchanged in the past 30 days.
Image: Bigstock
ZYN and IQOS Scale Up: Is Philip Morris Leading the Industry Reset?
Key Takeaways
Philip Morris International Inc. (PM - Free Report) is accelerating its shift from traditional tobacco to reduced-risk products, with strong momentum in its flagship offerings — IQOS and ZYN. In the first quarter of 2025, smoke-free products accounted for 44% of the company’s total gross profit, signaling significant progress toward its goal of becoming substantially smoke-free.
IQOS, Philip Morris’ heat-not-burn device, continues to be a global leader in next-gen nicotine delivery, delivering 9.4% growth in HTU-adjusted IMS, bolstered by solid performances in Japan and Europe. Meanwhile, ZYN, the oral nicotine pouch under Swedish Match (acquired in 2022), is quickly becoming a dominant force in the U.S. nicotine market. ZYN shipments surged 53% year over year to 202 million cans, with Philip Morris now expecting 800-840 million cans shipped in 2025, up from its prior forecast.
This surge is not just about volume — Philip Morris is seeing bottom-line benefits too. Smoke-free organic revenues rose 20.4%, while gross profit jumped 33.1%, pushing gross margin over 70%, far surpassing margins from combustible products. PM’s multi-category strategy — which also includes VEEV in the e-vapor space — is gaining traction, and its smoke-free products are now available in 95 countries with 38.6 million adult users globally.
With robust growth, margin expansion and strategic manufacturing investments in the United States, Philip Morris appears well-positioned to future-proof its portfolio. If current trends hold, the company could redefine its identity in a post-combustible world.
Altria & British American Tobacco Step Up Smoke-Free Competition
As Philip Morris pushes ahead in the smoke-free nicotine market, key rivals Altria Group, Inc. (MO - Free Report) and British American Tobacco p.l.c. (BTI - Free Report) are also accelerating their transition. Altria, known for Marlboro in the United States, is expanding its smoke-free portfolio through Helix Innovations, which owns 100% of on! nicotine pouches. In first-quarter 2025, on! shipments rose 18% year over year, driving stable growth in Altria’s Oral Tobacco segment, which posted $654 million in net revenues.
Meanwhile, British American Tobacco is targeting 50 million users of smoke-free products by 2030 and aims to generate 50% of revenues from this segment by 2035. In 2024, British American Tobacco’s New Category segment grew 2.5%, with 29.1 million adult users across products like Vuse (vapor), glo (heated) and Velo (oral nicotine). With both companies investing heavily in reduced-risk products, competition in the global smoke-free nicotine market continues to intensify.
PM’s Price Performance, Valuation & Estimates
Shares of Philip Morris have rallied 52.3% year to date compared with the industry’s growth of 37%.
Image Source: Zacks Investment Research
From a valuation standpoint, PM trades at a forward price-to-earnings ratio of 23.34X, above the industry’s average of 15.33X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for PM’s 2025 earnings implies year-over-year growth of 13.7%, whereas its 2026 earnings estimate suggests a year-over-year uptick of 11.7%. The estimates for 2025 and 2026 have remained unchanged in the past 30 days.
Image Source: Zacks Investment Research
PM stock currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.